



IOVERA[®] USE IN CHRONIC FOOT PAIN

REQUEST FOR PROPOSAL

BACKGROUND

Pacira BioSciences, Inc. is committed to supporting independent research initiatives that foster the advancement of scientific and clinical information and improve patient care. To that end, Pacira extends a new grant opportunity by way of a request for proposal (RFP) focused on research trials that seek to result in optimized patient care. These research trials will provide valued information on the efficacy of the company's marketed products.

All proposals are reviewed for scientific merit, innovation, clinical impact on patients, and compliance with Pacira policy and requirements. If you are interested in applying for support of a research proposal, please review the submission process and apply online by clicking [here](#). Pacira will review and consider all relevant research proposals but is not obligated to provide support for any research proposals received.

While the Pacira Grant Review Committee (PGRC) reviews all research proposals, the principal investigator (and ultimately the grantee) is responsible for the design, implementation, and conduct of the independent initiative supported by the grant. Pacira will not be involved in the conduct or monitoring of the proposed trial, including drafting the research study protocol.

PURPOSE AND INTENT

Pacira BioSciences, Inc. issues this RFP for a prospective clinical research study evaluating the iovera[®] system in chronic foot pain (eg, plantar fasciitis, Morton's neuroma). This RFP is funded through the investigator initiated trial (IIT) grant program at Pacira. Funding is available for the fiscal year 2020 and may be extended at the company's discretion.

ELIGIBILITY

To be eligible for consideration, the requestor must be an independent third party. Examples of appropriate requestors include, but are not limited to:

- Academic medical centers
- Healthcare institutions, including private practice settings and ambulatory care facilities

Note: If the research involves multiple departments within an institution and/or between different institutions/organizations/associations, please note each institution's role in the grant application.

TARGET AUDIENCE

Health care professionals involved in the care of patients with chronic foot pain.

TIMELINE

The RFP application will remain open until the grant has been awarded.

Note: The PGRC may award multiple awards at its discretion.

BURDEN

Epidemiology of chronic foot disorders

Plantar fasciitis or plantar fasciopathy is a disorder characterized by severe pain in the plantar fascia (ie, plantar surface of the foot). The plantar fascia is a fibrous sheath of tissue that supports the longitudinal arch of the foot and provides cushion on impact (1). Though the etiology of plantar fasciitis is unknown, the current theory is that the condition is caused by repetitive microtearing of the tissue (1). Risk factors for plantar fasciitis includes being a runner, obesity, shoe type, age, sex, having a high arch (pes cavus), pregnancy, abnormal gait pattern, or being flat-footed (pes planus) (2).

Plantar fasciitis affects more than one-million people in the United States and nearly two-thirds of the affected population will seek care (3). The 2013 National Health and Wellness Survey estimated that 0.85% of the sample population (n=75,000) reported diagnosed plantar fasciitis with a higher prevalence in women, older age, and obese (4).

Morton's neuroma is a painful condition that affects the ball of your foot, most commonly the area between the third and fourth toes. As Morton's neuroma (MN) is deemed a neuropathy, symptoms might include numbness, tingling, and burning. Overall, the rate of neuropathic pain in the ankle/hindfoot is 15.5%, 11.4% in the midfoot, and 7.5% in the forefoot (5).

Economic impact of chronic foot disorders

Although plantar fasciitis is a self-limiting condition in many cases, plantar fasciitis may still require treatment. It was estimated that approximately 1 million primary care visits per year were made between 1995–2000 where 62% of visits were made to primary care practitioners and 31% to orthopedic surgeons (6). Patient visits for plantar fasciitis accounted for approximately 1% of all patient visits to orthopedic surgeons. Overall the economic burden was reported to be between \$192 million and \$376 million (1).

Chronic foot disorders treatment

Current treatment options for plantar fasciitis include injections (eg, corticosteroids), lasers, orthoses, extracorporeal shock wave therapy, heel cups, heel pads, splints, non-steroidal anti-inflammatory drugs, cryotherapy (superficial cold therapy), taping, stretching exercises, ultrasound, surgery, and cryoanalgesia (7-10). Similar treatment approaches have been

recommended for Morton's neuroma including physical therapy, orthoses, radio-frequency ablation, corticosteroid and alcohol injections, neurotomy, and cryoablation (11, 12).

Unfortunately, current evidence does not support the use of one intervention over another and as with all interventions, the least invasive methods with the greatest safety profile should be employed first (7).

SCOPE OF WORK

The successful applicant will prepare a research proposal for a feasibility study that adequately addresses the management of chronic foot pain with cryoanalgesia using the iovera^o system.

The study proposal should focus on patients with chronic foot pain who have failed conservative therapies. The study will be a case series evaluating patients before and after cryoanalgesia treatment for up to six months with a 3-month enrollment period. Outcomes may include pain (eg, NRS, VAS), patient reported outcomes (eg, Foot & Ankle Ability Measure (FAAM), Foot Function Index (FFI), Foot Health Status Questionnaire (FHSQ)) and adverse events.

Grant recipients will receive training on the use of the iovera^o system and agree to provide data to Pacira at the time of study completion.

The Pacira Grant Review Committee will consider funding awards inclusive of indirect costs for the conduct of the study based on a budget within fair market value.

PROPOSAL SUBMISSION REQUIREMENTS

All requestors must submit a written proposal that addresses the following topics and includes required supporting documentation including:

- Organization's contact information
- Primary contact name, title, address, phone, and email
- Describe the organization's current activities relevant to the proposal including current standard of care and patient volume
- Project description and specific proposal objectives
- Available data/information relevant to proposal submission (eg, pilot data)
- Describe how the proposal will improve patient care in alignment with grant objectives
- Proposed timeline for completion with associated deliverables. If possible, attach a flow chart outlining the operational steps of the proposed program.
- Proposed budget that is within fair market value and reflects the scope of responsibilities to accomplish the goals of this project. No funding match is required; however, requestors will need to identify any other sources of funding, both in-kind and monetary, that will be used.

To apply for a grant, please click [here](#).

A letter of intent on organizational letterhead should be included. The letter of intent should be single-spaced and not exceed four pages (not including the reference page).

The RFP process

Pacira maintains a stepwise process for review of RFPs. In brief, after registering on the online grant portal, the principal investigator submits a brief concept proposal and if accepted after a review by the PGRC, will be invited to submit a full proposal. Details on brief and full proposal contents are below.

Brief concept proposal:

A brief concept proposal must contain an adequate amount of information for the PGRC to determine interest in requesting a full study proposal. When submitting a brief concept proposal, the following information will be requested (if applicable):

- Principal investigator contact information
- Brief background for the study
- Method of administration of the marketed product
- Primary study objectives/endpoints
- Estimated study timelines
- Estimated total study budget
- Estimated study drug or device(s)
- Preliminary grant request: funding, drug, device, or a combination thereof
- Experience as sponsor-investigator
- Letter of intent on the requesting institution's letterhead
- Curriculum vitae from the principal investigator dated within the last calendar year

The PGRC will review all concept proposals for scientific merit, innovation, clinical importance/potential impact on patients, and compliance with company policy and requirements. The PGRC will extend contingent approval to individual applicants to proceed to the second step of the process, which is the submission of a full study proposal. Applicants will be notified of the PGRC's decision via email, and the status will also be available on the portal. Please note that an invitation to submit a full study proposal does not guarantee the approval of funding.

Full study proposal:

A full study proposal submission must contain enough detail about the research study to enable the PGRC to make an evaluation on support. When submitting a full study proposal, the following information will be requested (if applicable):

- Principal investigator contact information
- Study type: non-clinical or clinical
- Objectives: primary and secondary
- Key inclusion and exclusion criteria
- Study design
- Efficacy variables/measures



- Safety variables/measures
- Adverse event/Serious adverse event reporting
- Decision points/statistical methods/interim analysis
- Study product regimens
- Ethical rationale for the study
- Study deliverables
- Value of the study
- Applicable scientific references
- Publication plan
- Research Setting: single-site or multi-site
- Detailed budget
- Grant request: funding, product, or a combination thereof

Pacira reserves the right to reconsider its support if the research objectives outlined in the final protocol are materially different from the approved full study proposal. Pacira will not compensate for any work performed before the execution of a final contract or for impermissible costs, which include:

- Construction funds to build new facilities
- General education and training activities
- Hiring of staff that are not dedicated to the proposed research study
- Study to involve new investigational products or devices
- Studies that are designed to generate business for Pacira
- Purchase of capital equipment unrelated to the study or that would generate revenue
- Requests for support for ongoing or new research without an associated research study protocol
- Start-up funds to establish new clinical or research programs or to expand existing programs
- Support for ongoing clinical programs that are part of an organization's routine operations

PACIRA BIOSCIENCES, INC. CONTACT INFORMATION

If you have questions regarding this RFP, please email grants@pacira.com and include in the subject line *chronic foot RFP*.

CONFIDENTIALITY

This Request for Proposal constitutes the confidential and proprietary information of Pacira BioSciences, Inc. and may not, in whole or in part, be copied, reproduced, or otherwise used in any manner whatsoever without the prior express written permission of Pacira BioSciences, Inc. All information provided herein is proprietary to Pacira BioSciences, Inc. and is to be used only by your company in its response hereto. Any other use or communication of this information is prohibited.

REFERENCES

1. Tong KB, Furia J. Economic burden of plantar fasciitis treatment in the United States. *American journal of orthopedics (Belle Mead, NJ)*. 2010;39(5):227-31.
2. Waclawski ER, Beach J, Milne A, Yacyshyn E, Dryden DM. Systematic review: plantar fasciitis and prolonged weight bearing. *Occupational medicine*. 2015;65(2):97-106.
3. Goff JD, Crawford R. Diagnosis and treatment of plantar fasciitis. *American family physician*. 2011;84(6):676-82.
4. Nahin RL. Prevalence and Pharmaceutical Treatment of Plantar Fasciitis in United States Adults. *The journal of pain : official journal of the American Pain Society*. 2018;19(8):885-96.
5. Sidon E, Rogero R, McDonald E, Daecher A, Shakked R, Pedowitz DI, et al. Prevalence of Neuropathic Pain Symptoms in Foot and Ankle Patients. *Foot Ankle Int*. 2019;40(6):629-33.
6. Riddle DL, Schappert SM. Volume of ambulatory care visits and patterns of care for patients diagnosed with plantar fasciitis: a national study of medical doctors. *Foot Ankle Int*. 2004;25(5):303-10.
7. Landorf KB, Menz HB. Plantar heel pain and fasciitis. *BMJ Clin Evid*. 2008;2008.
8. Healey K, Chen K. Plantar fasciitis: current diagnostic modalities and treatments. *Clin Podiatr Med Surg*. 2010;27(3):369-80.
9. Cavazos GJ, Khan KH, D'Antoni AV, Harkless LB, Lopez D. Cryosurgery for the Treatment of Heel Pain. *Foot & Ankle International*. 2009;30(6):500-6.
10. Catal B, Bilge A, Ulusoy RG. Endoscopic Plantar Fascia Release Versus Cryosurgery for The Treatment of Chronic Plantar Fasciitis: A Prospective Randomized Study. *J Am Podiatr Med Assoc*. 2019.
11. Valisena S, Petri GJ, Ferrero A. Treatment of Morton's neuroma: A systematic review. *Foot and ankle surgery : official journal of the European Society of Foot and Ankle Surgeons*. 2018;24(4):271-81.
12. Cazzato RL, Garnon J, Ramamurthy N, Tsoumakidou G, Caudrelier J, Thenint MA, et al. Percutaneous MR-Guided Cryoablation of Morton's Neuroma: Rationale and Technical Details After the First 20 Patients. *Cardiovasc Intervent Radiol*. 2016;39(10):1491-8.